PE20150187A1 - Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma - Google Patents
Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la mismaInfo
- Publication number
- PE20150187A1 PE20150187A1 PE2014002472A PE2014002472A PE20150187A1 PE 20150187 A1 PE20150187 A1 PE 20150187A1 PE 2014002472 A PE2014002472 A PE 2014002472A PE 2014002472 A PE2014002472 A PE 2014002472A PE 20150187 A1 PE20150187 A1 PE 20150187A1
- Authority
- PE
- Peru
- Prior art keywords
- diseases
- compound
- treatment
- pharmaceutical compositions
- aminotriazolopyridine
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- KGUHUVQIJHGHLX-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridin-5-amine Chemical compound NC1=CC=C2NN=NC2=N1 KGUHUVQIJHGHLX-UHFFFAOYSA-N 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 5
- 210000000845 cartilage Anatomy 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010010356 Congenital anomaly Diseases 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 2
- 108010050904 Interferons Proteins 0.000 abstract 2
- 206010052779 Transplant rejections Diseases 0.000 abstract 2
- 230000007815 allergy Effects 0.000 abstract 2
- 230000001771 impaired effect Effects 0.000 abstract 2
- 230000004968 inflammatory condition Effects 0.000 abstract 2
- 229940047124 interferons Drugs 0.000 abstract 2
- 230000036244 malformation Effects 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- BYWJAVQGRJEEHH-UHFFFAOYSA-N 5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound N12N=C(N)N=C2C=CC=C1C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 BYWJAVQGRJEEHH-UHFFFAOYSA-N 0.000 abstract 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 abstract 1
- 102000042838 JAK family Human genes 0.000 abstract 1
- 108091082332 JAK family Proteins 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
Referida a un compuesto Formula I (5-[4-(1,1-dioxotiomorfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-ilamina) y a composiciones que lo comprenden. Dicho compuesto es util en el tratamiento de afecciones inflamatorias, enfermedades autoinmunitarias, enfermedades proliferativas, alergias, rechazo de trasplante, enfermedades que implican un deterioro de la produccion de cartilago, malformaciones congenitas de los cartilagos y/o enfermedades asociadas con la hipersecrecion de IL6 o interferones. En particular, el compuesto inhibe JAK, una familia de tirosina cinasas, y mas particularmente JAK1. La invencion tambien proporciona composiciones farmaceuticas que comprenden el compuesto, metodos para la profilaxis y/o el tratamiento de enfermedades que incluyen afecciones inflamatorias, enfermedades autoinmunitarias, enfermedades proliferativas, alergias, rechazo de trasplante, enfermedades que implican un deterioro de la produccion de cartilago, malformaciones congenitas de los cartilagos y/o enfermedades asociadas con la hipersecrecion de IL6 o interferones a traves de la administracion del compuesto
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663520P | 2012-06-22 | 2012-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20150187A1 true PE20150187A1 (es) | 2015-02-27 |
Family
ID=48577773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014002472A PE20150187A1 (es) | 2012-06-22 | 2013-06-10 | Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US9284311B2 (es) |
| EP (1) | EP2863950B1 (es) |
| JP (2) | JP6238975B2 (es) |
| KR (1) | KR102078069B1 (es) |
| CN (2) | CN107998136A (es) |
| AR (1) | AR091395A1 (es) |
| AU (1) | AU2013279597B2 (es) |
| BR (1) | BR112014031626A8 (es) |
| CA (1) | CA2875619C (es) |
| CL (1) | CL2014003462A1 (es) |
| CO (1) | CO7160085A2 (es) |
| CR (1) | CR20140583A (es) |
| CY (1) | CY1120643T1 (es) |
| DK (1) | DK2863950T3 (es) |
| EA (1) | EA029084B1 (es) |
| ES (1) | ES2685985T3 (es) |
| HR (1) | HRP20181364T8 (es) |
| HU (1) | HUE038878T2 (es) |
| IL (1) | IL235923B (es) |
| LT (1) | LT2863950T (es) |
| MA (1) | MA37775A1 (es) |
| MX (1) | MX368511B (es) |
| MY (1) | MY177334A (es) |
| NZ (1) | NZ702480A (es) |
| PE (1) | PE20150187A1 (es) |
| PH (1) | PH12014502615B1 (es) |
| PL (1) | PL2863950T3 (es) |
| PT (1) | PT2863950T (es) |
| SG (2) | SG11201408123SA (es) |
| SI (1) | SI2863950T1 (es) |
| TW (1) | TWI586352B (es) |
| UA (1) | UA112804C2 (es) |
| UY (1) | UY34855A (es) |
| WO (1) | WO2013189771A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| GB201402071D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2016165953A1 (en) | 2015-04-13 | 2016-10-20 | Galapagos Nv | Methods for the treatment of inflammatory disorders |
| KR102747428B1 (ko) | 2015-04-13 | 2024-12-27 | 알파시그마 에스.피.에이. | 심혈관 질환의 치료 방법 |
| WO2016179207A1 (en) * | 2015-05-05 | 2016-11-10 | Concert Pharmaceuticals, Inc. | Deuterated filgotinib |
| CN105061420B (zh) * | 2015-06-04 | 2017-09-05 | 南京旗昌医药科技有限公司 | 一种jak抑制剂的晶型及其制备方法和应用 |
| WO2017106568A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer |
| US20170174788A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders |
| WO2017106564A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| WO2017133423A1 (zh) * | 2016-02-02 | 2017-08-10 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡啶酰胺类化合物及其应用 |
| US20190314382A1 (en) | 2016-11-10 | 2019-10-17 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases |
| GB201702603D0 (en) | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| JOP20180018A1 (ar) | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | تركيبات صيدلية تتضمن مثبط jak |
| GB201808575D0 (en) * | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
| WO2019246273A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| EP3947381A4 (en) * | 2019-03-30 | 2024-07-24 | Unichem Laboratories Ltd | Novel process for the preparation of filgotinib and intermediates thereof |
| JP7315166B2 (ja) * | 2019-06-10 | 2023-07-26 | 富士通株式会社 | グラフェンナノリボンネットワーク膜の製造方法及び電子装置の製造方法 |
| CN111686106B (zh) * | 2020-04-05 | 2022-07-15 | 温州医科大学附属第一医院 | 提高Dicer表达的化合物在制备药物中的应用 |
| CN114409675B (zh) * | 2022-01-07 | 2023-08-04 | 重庆医科大学 | 螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0716239A2 (pt) * | 2006-08-30 | 2013-08-13 | Cellzome Ltd | derivados de triazol como inibidores de cinase |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| WO2010141796A2 (en) * | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES |
| JO3030B1 (ar) * | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| TWI462920B (zh) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
-
2013
- 2013-06-10 PE PE2014002472A patent/PE20150187A1/es not_active Application Discontinuation
- 2013-06-10 AU AU2013279597A patent/AU2013279597B2/en active Active
- 2013-06-10 AR ARP130102033 patent/AR091395A1/es unknown
- 2013-06-10 SI SI201331137T patent/SI2863950T1/sl unknown
- 2013-06-10 BR BR112014031626A patent/BR112014031626A8/pt not_active Application Discontinuation
- 2013-06-10 ES ES13727625.9T patent/ES2685985T3/es active Active
- 2013-06-10 HU HUE13727625A patent/HUE038878T2/hu unknown
- 2013-06-10 CN CN201810014031.0A patent/CN107998136A/zh active Pending
- 2013-06-10 DK DK13727625.9T patent/DK2863950T3/en active
- 2013-06-10 UY UY0001034855A patent/UY34855A/es unknown
- 2013-06-10 LT LTEP13727625.9T patent/LT2863950T/lt unknown
- 2013-06-10 SG SG11201408123SA patent/SG11201408123SA/en unknown
- 2013-06-10 KR KR1020157001521A patent/KR102078069B1/ko active Active
- 2013-06-10 US US13/913,597 patent/US9284311B2/en active Active
- 2013-06-10 PL PL13727625T patent/PL2863950T3/pl unknown
- 2013-06-10 NZ NZ702480A patent/NZ702480A/en unknown
- 2013-06-10 MA MA37775A patent/MA37775A1/fr unknown
- 2013-06-10 WO PCT/EP2013/061914 patent/WO2013189771A1/en not_active Ceased
- 2013-06-10 MY MYPI2014703876A patent/MY177334A/en unknown
- 2013-06-10 CN CN201380032159.5A patent/CN104379173A/zh active Pending
- 2013-06-10 HR HRP20181364TT patent/HRP20181364T8/hr unknown
- 2013-06-10 MX MX2014014800A patent/MX368511B/es active IP Right Grant
- 2013-06-10 JP JP2015517666A patent/JP6238975B2/ja active Active
- 2013-06-10 EP EP13727625.9A patent/EP2863950B1/en active Active
- 2013-06-10 SG SG10201700125VA patent/SG10201700125VA/en unknown
- 2013-06-10 EA EA201590071A patent/EA029084B1/ru unknown
- 2013-06-10 CA CA2875619A patent/CA2875619C/en active Active
- 2013-06-10 PT PT13727625T patent/PT2863950T/pt unknown
- 2013-06-11 TW TW102120793A patent/TWI586352B/zh active
- 2013-10-06 UA UAA201500458A patent/UA112804C2/uk unknown
-
2014
- 2014-11-24 PH PH12014502615A patent/PH12014502615B1/en unknown
- 2014-11-26 IL IL235923A patent/IL235923B/en active IP Right Grant
- 2014-12-16 CR CR20140583A patent/CR20140583A/es unknown
- 2014-12-19 CO CO14279834A patent/CO7160085A2/es unknown
- 2014-12-19 CL CL2014003462A patent/CL2014003462A1/es unknown
-
2016
- 2016-03-14 US US15/069,130 patent/US20160296529A1/en not_active Abandoned
-
2017
- 2017-10-31 JP JP2017210372A patent/JP2018048185A/ja active Pending
-
2018
- 2018-08-29 CY CY181100902T patent/CY1120643T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20150187A1 (es) | Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma | |
| CL2011003247A1 (es) | Compuesto {5-[4-(1,1-dioxo-1-tiomorfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amida de acido ciclopropanocarboxilico, con actividad inhibidora de jak1 y jak2; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, autoinmunitarias, proliferativas, entre otras. | |
| CL2018001031A1 (es) | Inhibidores de ferroportina novedosos | |
| CL2017002650A1 (es) | Compuestos novedosos | |
| CL2016001055A1 (es) | Compuestos derivados de fenil-aminopirimidina, inhibidores de la tirosina quinasa de bruton (btk), composicion farmaceutica; combinacion farmaceutica; útiles en el tratamiento de enfermedades autoinmunes, inflamatorias, alergicas, de las vias aereas, entre otras. | |
| MX2013001970A (es) | Compuestos de pirrolopirimidina y usos de los mismos. | |
| AR077221A1 (es) | {5-[4-(3,3-dimetil-azetidina-1-carbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il} amida del acido ciclopropanocarboxilico inhibidor de quinasas janus(jak), en particular jak1, composiciones farmaceuticas que lo contienen y uso de los mismos para tratar afecciones inflamatorias, autoinmunes y proli | |
| CL2014002412A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras. | |
| CL2011002115A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| CO7240408A2 (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| CR20130617A (es) | Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
| MX2014010589A (es) | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso. | |
| CL2015000530A1 (es) | Compuestos derivados ciclicos eter pirazol-4-il-heterociclil-carboxamida, como inhibidores de la quinasa pim; composicion farmaceutica que los comprende; y su uso para el tratamiento de cancer, trastornos inmunologicos, enfermedades cardiovasculares, infeccion virica, inflamacion, trastornos del metabolismo/funcion endocrina y trastornos neurologicos. | |
| BR112015019508A8 (pt) | formas sólidas de um inibidor de cdk4/6 seletivo | |
| CR20160076A (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA | |
| ECSP14004812A (es) | Triazolopiridinas sustituidas | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| CR20140113A (es) | Imidazopiridazinas sustituidas con amino | |
| PE20170703A1 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos | |
| ECSP15031046A (es) | Polipéptidos estabilizados del factor de crecimiento tipo insulina | |
| CL2017001615A1 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2. | |
| CL2013003056A1 (es) | Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas. | |
| CL2011003355A1 (es) | Compuestos derivados de alcoxi-carbonil-amino-alquinil-adenosina ; composición farmacéutica que los comprende; uso del compuesto en la preparación de un medicamento útil para tratar enfermedades autoinmunes, inflamatorias, alérgicas, infecciosas entre otras. | |
| UY34630A (es) | Imidazopiridazinas sustituidas con amino |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |